Last reviewed · How we verify
NCT00005874
Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas
Phase 2 trial testing rubitecan in Gastrointestinal Stromal Tumor. Completed in 1 April 2004.
Quick facts
| Lead sponsor | Astex Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Primary purpose | treatment |
| Start date | 1 June 1999 |
| Estimated completion | 1 April 2004 |
| Sites | 1 location across United States |
Drugs / interventions tested
- rubitecan — full drug profile →
Conditions studied
- Gastrointestinal Stromal Tumor — all drugs for Gastrointestinal Stromal Tumor →
- Sarcoma — all drugs for Sarcoma →
- Small Intestine Cancer — all drugs for Small Intestine Cancer →
Sponsor
Astex Pharmaceuticals, Inc. — full company profile →
Who can join
Eligibility, any sex, with Gastrointestinal Stromal Tumor or Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally advanced or metastatic soft tissue sarcomas.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00005874
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastrointestinal Stromal Tumor
Currently open trials in the same condition.
- NCT04933669 — Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors · Phase 2 · recruiting
- NCT02834013 — Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · Phase 2 · active not recruiting
- NCT00265798 — Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Tr · Phase 2 · active not recruiting
Other Astex Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT05835011 — A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-R · Phase 2 · terminated
- NCT04953923 — Thorough QT Assessment of Cedazuridine in Healthy Subjects · Phase 1 · completed
- NCT04637009 — A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms · Phase 1 · terminated
- NCT04466514 — A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029 · Phase 1 · completed
- NCT04479800 — Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00005874 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Astex Pharmaceuticals, Inc.
- Last refreshed: 3 December 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00005874.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing